The effectiveness of FloSeal matrix hemostatic agent in thyroid surgery: a prospective, randomized, control study

Langenbecks Arch Surg. 2009 Sep;394(5):837-42. doi: 10.1007/s00423-009-0497-5. Epub 2009 May 7.

Abstract

Background: The objective of this study was to compare the effectiveness of FloSeal matrix hemostatic agent with hemostatic surgical procedures and Tabotamp in thyroid surgery.

Methods: One hundred fifty-five consecutive total thyroidectomy patients were recruited at our institution between January 2005 and December 2007. Exclusion criteria were applied. Patients were randomized to one of three hemostatic approaches: 49 received surgical procedures only, and 52 received oxidized regenerated cellulose patch (Tabotamp Fibrillar 2.5 x 5 cm) and 54 FloSeal (5,000 U/5 mL). The same surgeon performed all operations.

Results: Mean operating time was reduced in the FloSeal group (105 min) vs. surgical (133 min, p = 0.02) and vs. Tabotamp (122 min, p = 0.0003). Also, wound drain removal occurred earlier with FloSeal (p = 0.006 vs. surgical; p = 0.008 vs. Tabotamp) resulting in shorter postoperative hospital stay in the FloSeal group (p = 0.02 vs. surgical; p = 0.002 vs. Tabotamp).

Conclusions: FloSeal matrix is an effective additional agent to conventional haemostatic procedures in thyroid surgery.

Publication types

  • Comparative Study
  • Randomized Controlled Trial

MeSH terms

  • Adolescent
  • Adult
  • Aged
  • Aged, 80 and over
  • Female
  • Gelatin Sponge, Absorbable / therapeutic use*
  • Hemostasis, Surgical*
  • Hemostatics / therapeutic use
  • Humans
  • Length of Stay
  • Male
  • Middle Aged
  • Postoperative Complications
  • Thyroidectomy* / adverse effects
  • Young Adult

Substances

  • FloSeal Matrix
  • Hemostatics